Additionally, two key molecules, glucose-regulated protein 94 (GRP94) and nuclear protein p54(nrb)/Nono, can regulate the SREBP-1 signaling pathway in in vitro and in vivo models, which have been potential targets for breast cancer treatment (84, 85). This evidence concerns the gene NONO and breast carcinoma.